Loading

Case Report Open Access
Volume 2 | Issue 1 | DOI: https://doi.org/10.46439/allergy.2.018

Severe SARS-CoV-2 infection treated with the mannose binding lectin associated serine protease 2 (MASP2) inhibitor Narsoplimab

  • 1Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
  • 2Brownsburg North Family Medicine, Brownsburg, IN 46112, USA
+ Affiliations - Affiliations

Corresponding Author

Robert J. Konrad, M.D, konrad_robert@lilly.com

Received Date: March 15, 2021

Accepted Date: April 29, 2021

Abstract

In SARS-CoV-2 infection, increased inflammation, complement activation, and excessive clotting are responsible for morbidity and mortality. Recent reports suggest that mannose binding lectin (MBL) and mannose-associated serine protease 2 (MASP2) lies at the intersection of these pathways. Consistent with this concept, we observed that the SARS-CoV-2 spike protein binds MBL-MASP1/2 complex in human serum.

Keywords

SARS-CoV-2, Narsoplimab, COVID-19, MBL, MASP2

Author Information X